anti-CS1 CAR T-cell therapy (Ohio State University Comprehensive Cancer Center/Cellectis)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CS1 CAR T-cell therapy (Ohio State University Comprehensive Cancer Center/Cellectis)
Drug Alias Nameanti-SLAMF7 CAR T-cell therapy (Ohio State University Comprehensive Cancer Center/Cellectis)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionSLAM family member 7 modulators
TargetsSLAM family member 7
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesOhio State University Comprehensive Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCellectis SaOhio State University Comprehensive Cancer Center
Active IndicationsN/A
Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A